Advances in Mycobacterium tuberculosis regulation of host lipid metabolism reprogramming

doi:10.19982/j.issn.1000-6621.20260098

Abstract

Abstract:

Tuberculosis is a major global infectious disease caused by Mycobacterium tuberculosis (MTB). The pathogen’s ability to establish long-term persistence and evade host immunity is central to the development of chronic infection. Lipid metabolism plays a pivotal role in host-pathogen interactions: MTB not only actively hijacks host lipids as a nutrient source but also systematically reprograms the host lipid metabolic network to evade immune clearance and establish persistent infection. A deeper understanding of the molecular mechanisms by which MTB hijacks and reprograms host lipid metabolism provides important theoretical foundations and potential targets for the development of host-directed therapies focusing on host lipid metabolism. This review systematically summarizes the molecular mechanisms by which MTB hijacks host lipids as a nutrient source and reprograms host lipid metabolism to achieve immune evasion, and discusses future research directions and clinical translation prospects in this field.

Key words: Mycobacterium tuberculosis, Macrophages, Lipid metabolism, Host-pathogen interactions

CLC Number:

R378.91

Zeng Lina, Li Wensi, Lu Hailin, Wang Wenfei, Chen Xinchun, Deng Guofang, Xie Shuixiang. Advances in Mycobacterium tuberculosis regulation of host lipid metabolism reprogramming[J]. Chinese Journal of Antituberculosis, 2026, 48(8): 1214-1219. doi: 10.19982/j.issn.1000-6621.20260098

References 54

[1]	World Health Organization. Global tuberculosis report 2025[R]. Geneva: World Health Organization, 2025.
[2]	屈燕, 李涛, 马文斌, 等. 世界卫生组织《2025年全球结核病报告》解读[J]. 结核与肺部疾病杂志, 2025, 6(6): 613-623. doi:10.19983/j.issn.2096-8493.20250178.
[3]	李晓雪, 肖筱, 徐春华, 等. 活动性结核病患者密切接触者结核分枝杆菌潜伏感染率的Meta分析[J]. 结核与肺部疾病杂志, 2024, 5(5): 404-414. doi:10.19983/j.issn.2096-8493.2024128.
[4]	徐雁南, 方梓昊, 赵文丽, 等. 中国异烟肼耐药结核分枝杆菌基因突变特征分析[J]. 结核与肺部疾病杂志, 2025, 6(1): 14-21. doi:10.19983/j.issn.2096-8493.2024118.
[5]	何繁漪, 陆霓虹, 杜映荣. 结核病与COVID-19相互作用的研究进展[J]. 结核与肺部疾病杂志, 2024, 5(4): 345-351. doi:10.19983/j.issn.2096-8493.2024045.
[6]	梁晨, 唐神结, 林明贵. 结核病综合治疗研究进展[J]. 结核与肺部疾病杂志, 2024, 5(1): 70-80. doi:10.19983/j.issn.2096-8493.20230112.
[7]	Cohen S B, Gern B H, Urdahl K B. The Tuberculous Granuloma and Preexisting Immunity[J]. Annu Rev Immunol, 2022, 40: 589-614. doi:10.1146/annurev-immunol-093019-125148. pmid: 35130029
[8]	Guerrini V, Prideaux B, Blanc L, et al. Storage lipid studies in tuberculosis reveal that foam cell biogenesis is disease-specific[J]. PLoS Pathog, 2018, 14(8): e1007223. doi:10.1371/journal.ppat.1007223.
[9]	Olzmann J A, Carvalho P. Dynamics and functions of lipid droplets[J]. Nat Rev Mol Cell Biol, 2019, 20(3):137-155. doi:10.1038/s41580-018-0085-z.
[10]	Pisu D, Huang L, Narang V, et al. Single cell analysis of M.tuberculosis phenotype and macrophage lineages in the infected lung[J]. J Exp Med, 2021, 218(9): e20210615. doi:10.1084/jem.20210615.
[11]	肖文静, 沈鑫. 进一步推进结核分枝杆菌潜伏感染管理加快实现终结结核病目标[J]. 结核与肺部疾病杂志, 2024, 5(5): 385-387. doi:10.19983/j.issn.2096-8493.2024138.
[12]	闭德武, 罗晓成, 何华伟, 等. 618例耐多药结核病患者流行病学特征研究[J]. 结核与肺部疾病杂志, 2025, 6(S1): 47-51. doi:10.19983/j.issn.2096-8493.20253076.
[13]	段鸿飞. 《世界卫生组织endTB方案治疗耐多药结核病指南》解读[J]. 结核与肺部疾病杂志, 2025, 6(4): 361-364. doi:10.19983/j.issn.2096-8493.20250030.
[14]	阿卜力米提·阿卜杜喀迪尔, 李佩波, 谢建平. 2024年全球结核病药物研发进展:多靶点策略、耐药机制突破与个体化治疗[J]. 结核与肺部疾病杂志, 2025, 6(5): 587-597. doi:10.19983/j.issn.2096-8493.20250049.
[15]	Bates T A, Trank-Greene M, Wrynla X H, et al. ESAT-6 undergoes self-association at phagosomal pH and an ESAT-6-specific nanobody restricts M.tuberculosis growth in macrophages[J]. Elife, 2024, 12:RP91930. doi:10.7554/eLife.91930.
[16]	Araujo C D N, Silva F, Zimpel C K, et al. Comparative pathoadaptation of Mycobacterium canettii and Mycobacterium tuberculosis: Insights from assays on phagosome acidification, cytosolic access, and transcriptomics[J]. Microbes Infect, 2025, 27(4): 105503. doi:10.1016/j.micinf.2025.105503.
[17]	Greenwood D J, Dos Santos M S D, Huang S, et al. Subcellular antibiotic visualization reveals a dynamic drug reservoir in infected macrophages[J]. Science, 2019, 364(6447): 1279-1282. doi:10.1126/science.aat9689. pmid: 31249058
[18]	Lovewell R R, Sassetti C M, VanderVen B C. Chewing the fat: lipid metabolism and homeostasis during M.tuberculosis infection[J]. Curr Opin Microbiol, 2016, 29: 30-36. doi:10.1016/j.mib.2015.10.002. pmid: 26544033
[19]	Yang X, Nesbitt N M, Dubnau E, et al. Cholesterol metabolism increases the metabolic pool of propionate in Mycobacterium tuberculosis[J]. Biochemistry, 2009, 48(18): 3819-3821. doi:10.1021/bi9005418.
[20]	Griffin J E, Gawronski J D, Dejesus M A, et al. High-resolution phenotypic profiling defines genes essential for mycobacterial growth and cholesterol catabolism[J]. PLoS Pathog, 2011, 7(9): e1002251. doi:10.1371/journal.ppat.1002251.
[21]	Chen Z, Kong X, Ma Q, et al. The impact of Mycobacterium tuberculosis on the macrophage cholesterol metabolism pathway[J]. Front Immunol, 2024, 15: 1402024. doi:10.3389/fimmu.2024.1402024.
[22]	Santucci P, Smichi N, Diomandé S, et al. Dissecting the membrane lipid binding properties and lipase activity of Mycobacterium tuberculosis LipY domains[J]. FEBS J, 2019, 286(16): 3164-3181. doi:10.1111/febs.14864. pmid: 31034693
[23]	Singh V K, Srivastava M, Dasgupta A, et al. Increased virulence of Mycobacterium tuberculosis H37Rv overexpressing LipY in a murine model[J]. Tuberculosis (Edinb), 2014, 94(3): 252-261. doi:10.1016/j.tube.2014.02.001.
[24]	Delorme V, Diomandé S V, Dedieu L, et al. MmPPOX inhibits Mycobacterium tuberculosis lipolytic enzymes belonging to the hormone-sensitive lipase family and alters mycobacterial growth[J]. PLoS One, 2012, 7(9):e46493. doi:10.1371/journal.pone.0046493.
[25]	Zimmermann M, Kogadeeva M, Gengenbacher M, et al. Integration of Metabolomics and Transcriptomics Reveals a Complex Diet of Mycobacterium tuberculosis during Early Macrophage Infection[J]. mSystems, 2017, 2(4):e00057-17. doi:10.1128/mSystems.00057-17.
[26]	Negi A, Perveen S, Kour H, et al. Elucidating the potential of novel class biphenyl-phenyl acetate, IDD-AN-A1, an inhibitor targeting Isocitrate Lyase in Mycobacterium tuberculosis: A target to lead approach[J]. Bioorg Chem, 2026, 170: 109557. doi:10.1016/j.bioorg.2026.109557.
[27]	Gengenbacher M, Kaufmann S H. Mycobacterium tuberculosis: success through dormancy[J]. FEMS Microbiol Rev, 2012, 36(3):514-532. doi:10.1111/j.1574-6976.2012.00331.x.
[28]	Ishikawa E, Mori D, Yamasaki S. Recognition of Mycobacterial Lipids by Immune Receptors[J]. Trends Immunol, 2017, 38(1):66-76. doi:10.1016/j.it.2016.10.009. pmid: 27889398
[29]	刘权贤, 赵昭亮, 宗兆婧, 等. pks5基因(Rv1527c)缺失削弱结核分枝杆菌巨噬细胞内生存能力并调控炎症因子表达[J]. 结核与肺部疾病杂志, 2025, 6(6): 747-752. doi:10.19983/j.issn.2096-8493.20250101.
[30]	Shimano H, Sato R. SREBP-regulated lipid metabolism: convergent physiology-divergent pathophysiology[J]. Nat Rev Endocrinol, 2017, 13(12):710-730. doi:10.1038/nrendo.2017.91.
[31]	Luo J, Yang H, Song B L. Mechanisms and regulation of cholesterol homeostasis[J]. Nat Rev Mol Cell Biol, 2020, 21(4):225-245. doi:10.1038/s41580-019-0190-7.
[32]	Kidani Y, Elsaesser H, Hock M B, et al. Sterol regulatory element-binding proteins are essential for the metabolic programming of effector T cells and adaptive immunity[J]. Nat Immunol, 2013, 14(5):489-499. doi:10.1038/ni.2570. pmid: 23563690
[33]	Mahajan S, Dkhar H K, Chandra V, et al. Mycobacterium tuberculosis modulates macrophage lipid-sensing nuclear receptors PPARγ and TR4 for survival[J]. J Immunol, 2012, 188(11):5593-5603. doi:10.4049/jimmunol.1103038. pmid: 22544925
[34]	Febbraio M, Silverstein R L. CD36: implications in cardiovascular disease[J]. Int J Biochem Cell Biol, 2007, 39(11): 2012-2030. doi:10.1016/j.biocel.2007.03.012.
[35]	Dodd C E, Pyle C J, Glowinski R, et al. CD36-Mediated Uptake of Surfactant Lipids by Human Macrophages Promotes Intracellular Growth of Mycobacterium tuberculosis[J]. J Immunol, 2016, 197(12): 4727-4735. doi:10.4049/jimmunol.1600856.
[36]	Maceiras A R, Silva M L, Couto J, et al. Activation of nuclear receptors correlates with tuberculosis severity and is a target for host-directed therapy[J]. Front Cell Infect Microbiol, 2025, 15:1724798. doi:10.3389/fcimb.2025.1724798.
[37]	Wilson J L, Mayr H K, Weichhart T. Metabolic Programming of Macrophages: Implications in the Pathogenesis of Granulomatous Disease[J]. Front Immunol, 2019, 10: 2265. doi:10.3389/fimmu.2019.02265. pmid: 31681260
[38]	Singh V, Jamwal S, Jain R, et al. Mycobacterium tuberculosis-driven targeted recalibration of macrophage lipid homeostasis promotes the foamy phenotype[J]. Cell Host Microbe, 2012, 12(5): 669-681. doi:10.1016/j.chom.2012.09.012. pmid: 23159056
[39]	Knight M, Braverman J, Asfaha K, et al. Lipid droplet formation in Mycobacterium tuberculosis infected macrophages requires IFN-γ/HIF-1α signaling and supports host defense[J]. PLoS Pathog, 2018, 14(1): e1006874. doi:10.1371/journal.ppat.1006874.
[40]	Listenberger L L, Han X, Lewis S E, et al. Triglyceride accumulation protects against fatty acid-induced lipotoxicity[J]. Proc Natl Acad Sci U S A, 2003, 100(6): 3077-3082. doi:10.1073/pnas.0630588100.
[41]	Filali-Mouncef Y, Hunter C, Roccio F, et al. The ménage à trois of autophagy, lipid droplets and liver disease[J]. Autophagy, 2022, 18(1): 50-72. doi:10.1080/15548627.2021.1895658.
[42]	Bosch M, Sánchez-Álvarez M, Fajardo A, et al. Mammalian lipid droplets are innate immune hubs integrating cell metabolism and host defense[J]. Science, 2020, 370(6514): eaay8085. doi:10.1126/science.aay8085.
[43]	Braverman J, Sogi K M, Benjamin D, et al. HIF-1α Is an Essential Mediator of IFN-γ-Dependent Immunity to Mycobacterium tuberculosis[J]. J Immunol, 2016, 197(4):1287-1297. doi:10.4049/jimmunol.1600266. pmid: 27430718
[44]	Huang L, Nazarova E V, Tan S, et al. Growth of Mycobacterium tuberculosis in vivo segregates with host macrophage metabolism and ontogeny[J]. J Exp Med, 2018, 215(4):1135-1152. doi:10.1084/jem.20172020.
[45]	Valm A M, Cohen S, Legant W R, et al. Applying systems-level spectral imaging and analysis to reveal the organelle interactome[J]. Nature, 2017, 546(7656): 162-167. doi:10.1038/nature22369.
[46]	Dejgaard S Y, Presley J F. Rab18: new insights into the function of an essential protein[J]. Cell Mol Life Sci, 2019, 76(10):1935-1945. doi:10.1007/s00018-019-03050-3. pmid: 30830238
[47]	Du X, Zhou L, Aw Y C, et al. ORP5 localizes to ER-lipid droplet contacts and regulates the level of PI(4)P on lipid droplets[J]. J Cell Biol, 2020, 219(1): e201905162. doi:10.1083/jcb.201905162.
[48]	Petrilli J D, Estevão P, De Araújo L E, et al. Immunoregulatory macrophages induced by mycobacterial nonpolar lipids[J]. J Immunol, 2025, 214(5): 1059-1070. doi:10.1093/jimmun/vkae058. pmid: 40280187
[49]	Dawa S, Menon D, Arumugam P, et al. Inhibition of Granuloma Triglyceride Synthesis Imparts Control of Mycobacterium tuberculosis Through Curtailed Inflammatory Responses[J]. Front Immunol, 2021, 12: 722735. doi:10.3389/fimmu.2021.722735.
[50]	Pellegrini J M, Martin C, Morelli M P, et al. PGE2 displays immunosuppressive effects during human active tuberculosis[J]. Sci Rep, 2021, 11(1):13559. doi:10.1038/s41598-021-92667-1. pmid: 34193890
[51]	Cumming B M, Addicott K W, Adamson J H, et al. Mycobacterium tuberculosis induces decelerated bioenergetic metabolism in human macrophages[J]. Elife, 2018, 7: e39169. doi:10.7554/eLife.39169.
[52]	Divakaruni A S, Hsieh W Y, Minarrieta L, et al. Etomoxir Inhibits Macrophage Polarization by Disrupting CoA Homeos-tasis[J]. Cell Metab, 2018, 28(3):490-503.e7. doi:10.1016/j.cmet.2018.06.001. pmid: 30043752
[53]	Mishra B B, Lovewell R R, Olive A J, et al. Nitric oxide prevents a pathogen-permissive granulocytic inflammation during tuberculosis[J]. Nat Microbiol, 2017, 2: 17072. doi:10.1038/nmicrobiol.2017.72. pmid: 28504669
[54]	Sen K, Biswas V K, Ghosh A, et al. NCoR1: a key player regulating mycobacterium tuberculosis pathogenesis[J]. Autophagy, 2024, 20(3): 697-698. doi:10.1080/15548627.2023.2277583.